| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.03B | $3.62B | $2.91B | $2.45B | $1.93B | $1.48B | $1.03B | $718.50M |
| Cost of Revenue | $1.59B | $1.33B | $1.03B | $768.00M | $646.60M | $544.50M | $367.70M | $226.40M |
| Gross Profit | $2.44B | $2.29B | $1.88B | $1.68B | $1.28B | $931.50M | $663.90M | $492.10M |
| Gross Margin | 60.46% | 63.19% | 64.72% | 68.63% | 66.44% | 63.11% | 64.36% | 68.49% |
| Operating Expenses | $1.84B | $1.69B | $1.49B | $1.41B | $980.60M | $789.20M | $850.20M | $534.60M |
| Operating Income | $600.00M | $597.70M | $391.20M | $265.80M | $299.50M | $142.30M | $-186.30M | $-42.50M |
| Operating Margin | 14.88% | 16.50% | 13.44% | 10.86% | 15.54% | 9.64% | -18.06% | -5.92% |
| Net Income | $576.20M | $541.50M | $341.20M | $216.90M | $493.60M | $101.10M | $-127.10M | $-50.20M |
| Net Margin | 14.29% | 14.95% | 11.73% | 8.86% | 25.62% | 6.85% | -12.32% | -6.99% |
| EPS (Basic) | $1.46 | $1.44 | $0.88 | $0.56 | $1.31 | $0.28 | $-0.36 | $-0.15 |
| EBITDA | $945.70M | $916.70M | $565.30M | $377.50M | $376.80M | $213.20M | $-74.70M | $-19.70M |
| Stock Option Compensation Expense | $170.40M | $150.80M | $126.50M | $113.40M | $119.40M | $102.70M | $101.90M | $106.20M |
| Price To Earnings Ratio | 54.61 | 88.46 | 129.24 | 239.45 | 70.71 | 197.12 | -83.13 | -98.68 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $31.47B | $47.90B | $44.10B | $51.94B | $34.90B | $19.93B | $10.57B | $4.95B |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $6.48B | $6.26B | $5.39B | $4.93B | $4.29B | $2.40B | $1.92B | $904.10M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.38B | $4.20B | $3.26B | $2.89B | $2.46B | $1.51B | $1.25B | $484.70M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $2.10B | $2.07B | $2.13B | $2.04B | $1.83B | $882.60M | $663.30M | $419.40M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $2.10B | $2.07B | $2.13B | $2.04B | $1.83B | $882.60M | $663.30M | $419.40M |
| Total Liabilities & Stockholders Equity | $6.48B | $6.26B | $5.39B | $4.93B | $4.29B | $2.40B | $1.92B | $904.10M |
| Book Value Per Share | $5.20 | $5.36 | $5.47 | $5.28 | $4.84 | $2.42 | $1.88 | $1.21 |
| Tangible Book Value Per Share | $4.88 | $4.95 | $4.96 | $5.13 | $4.73 | $2.37 | $1.83 | $1.18 |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 8.89% | 8.64% | 6.33% | 4.40% | 11.50% | 4.22% | -6.63% | -5.55% |
| Return on Equity | 27.40% | 26.18% | 16.01% | 10.62% | 27.02% | 11.45% | -19.16% | -11.97% |
| Return on Invested Capital | 10.20% | 9.63% | 7.86% | 5.30% | 8.11% | 6.74% | -11.00% | -5.55% |
| Quick Ratio | 1.28 | 2.48 | 1.83 | 4.62 | 5.19 | 5.13 | 7.32 | 5.04 |
| Current Ratio | 1.47 | 2.84 | 1.99 | 5.11 | 5.58 | 5.47 | 7.64 | 5.36 |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $576.20M | $541.50M | $341.20M | $216.90M | $493.60M | $101.10M | $-127.10M | $-50.20M |
| Depreciation | $217.70M | $186.00M | $155.90M | $101.90M | $67.10M | $48.70M | $29.10M | $16.10M |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $989.50M | $748.50M | $669.50M | $442.50M | $475.60M | $314.50M | $123.20M | $92.00M |
| Capital Expenditures | $358.80M | $236.60M | $364.80M | $389.20M | $199.00M | $180.00M | $67.10M | $66.00M |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | $750.00M | $688.70M | $557.70M | $0.00 | $0.00 | $0.00 | $100.00M | $0.00 |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $630.70M | $511.90M | $304.70M | $53.30M | $276.60M | $134.50M | $56.10M | $26.00M |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Why it moved over time
A law firm is soliciting Dexcom (DXCM) shareholders over alleged insider breaches of fiduciary duty, raising the prospect of shareholder claims or litigation and increased governance scrutiny.
Key fact: PR Newswire says shareholders are urged to contact the firm about alleged insider fiduciary breaches and that the firm would handle matters on a contingent-fee basis.
prnewswire.com: Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?Dexcom (DXCM) was likely driven by American Capital Management's 13F purchase of 235,152 shares, signaling notable institutional buying that can boost demand and investor sentiment.
Key fact: American Capital Management bought 235,152 DexCom shares, valued at about $15,837,000, per its recent 13F filing.
defenseworld.net: American Capital Management Inc. Purchases Shares of 235,152 DexCom, Inc. $DXCMDexcom (DXCM) drew fresh institutional buying after Aurora Investment Counsel disclosed a new 34,744-share (~$2.34M) stake, signaling renewed investor interest that could boost demand.
Key fact: Aurora Investment Counsel bought 34,744 DexCom shares valued at approximately $2.34 million, making DexCom 1.2% of its portfolio.
defenseworld.net: Aurora Investment Counsel Invests $2.34 Million in DexCom, Inc. $DXCMDexcom (DXCM) is drawing attention after Aurora Investment Counsel disclosed a new stake of 34,744 shares (~$2.34M), indicating fresh institutional buying that can bolster short-term investor interest.
Key fact: Aurora Investment Counsel bought 34,744 DXCM shares valued at approximately $2.34 million, per SEC filing.
defenseworld.net: Aurora Investment Counsel Invests $2.34 Million in DexCom, Inc. $DXCMDexcom raised its 2026 revenue and margin outlook, citing G7 15 Day rollout efficiencies that could boost profitability and sustain growth.
Key fact: Raised 2026 revenue and margin outlook due to G7 15 Day efficiency gains.
zacks.com: Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?Dexcom (DXCM) reported strong Q2 results and raised FY26 guidance, signaling G7 adoption, margin expansion and ongoing buybacks that support accelerating revenue and earnings visibility.
Key fact: Q2: 13.1% revenue growth and 49.7% operating income growth; company raised FY26 guidance.
seekingalpha.com: DexCom: Still A Cautious Buy Following EarningsDexcom reported Q2 revenue up 13% to $1.31 billion, beat EPS estimates and raised full-year revenue guidance, signaling sustained demand for its continuous glucose monitors and an improved outlook.
Key fact: Q2 revenue $1.31 billion (+13% y/y); EPS $0.70 vs. $0.61 estimate; raised full-year revenue forecast.
gurufocus.com: DexCom Inc (DXCM) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Signal Robust MomentumInvestors are focused on DexCom's upcoming Q2 earnings and guidance, as analyst coverage highlights margin pressure from tariffs and inflation plus G7 adoption and reimbursement expansion that could affect revenue and margins.
Key fact: Recent coverage (Zacks, other outlets) emphasizes Q2 results will reflect G7 adoption, broader reimbursement and potential margin pressure from tariffs and inflation.
fool.com: 3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold